Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

PURPOSE: Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clinical trials. E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m(2)/30 minutes versus GE...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Poplin, Elizabeth, Feng, Yang, Berlin, Jordan, Rothenberg, Mace L., Hochster, Howard, Mitchell, Edith, Alberts, Steven, O'Dwyer, Peter, Haller, Daniel, Catalano, Paul, Cella, David, Benson, Al Bowen
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2009
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727286/
https://ncbi.nlm.nih.gov/pubmed/19581537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.9007
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы